| Overview |
| bs-9555R-Cy7 |
| GLT8D1 Polyclonal Antibody, Cy7 Conjugated |
| WB, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GLT8D1 |
| 201-300/371 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 55830 |
| MGC94018; Da2 24; GALA4A; Glycosyltransferase 8 domain containing 1; Glycosyltransferase 8 domain-containing protein 1; Glycosyltransferase AD 017; MSTP139; GL8D1_HUMAN. |
| GLT8D1 is a 371 amino acid single-pass type II transmembrane protein that is expressed by a gene residing on human chromosome 3. Chromosome 3 is made up of about 214 million bases encoding over 1,100 genes, including a chemokine receptor (CKR) gene cluster and a variety of human cancer-related gene loci. Key tumor suppressing genes on chromosome 3 include those that encode the apoptosis mediator RASSF1, the cell migration regulator HYAL1 and the angiogenesis suppressor SEMA3B. Marfan Syndrome, porphyria, von Hippel-Lindau syndrome, osteogenesis imperfecta and Charcot-Marie-Tooth Disease are a few of the numerous genetic diseases associated with chromosome 3. There are two isoforms of GLT8D1 that are produced as a result of alternative splicing events. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz